Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 12, 2023CNS Neuroscience & TherapeuticsOpen Access

Clinical and preclinical evaluation of miR‐144‐5p as a key target for major depressive disorder

View Full Paper
Ask AI
Bookmark
Share

Authors

XWXiaodong WuYZYulong ZhangPWPing Wang

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Wu et al. (2023) studied this question.

synapsesocial.com/papers/6a79e02cb2ad017e40321682https://doi.org/10.1111/cns.14291
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A blood based 12-miRNA signature of Alzheimer disease patients2013 · 515 citations
  2. 2Depression Is the Leading Cause of Disability Around the World2017 · 1,509 citations
  3. 3Targeted electrode-based modulation of neural circuits for depression2009 · 541 citations
  4. 4TNFAIP3, a negative regulator of the TLR signaling pathway, is a potential predictive biomarker of response to antidepressant treatment in major depressive disorder2016 · 57 citations
  5. 5PTEN-mediated akt/β-Catenin/foxo1 signaling regulates innate immune responses in mouse liver ischemia/reperfusion injury2012 · 98 citations